In contrast to conventional cardiac ablation techniques, PFA therapy targets specific cardiac tissue regions with high-energy electrical pulses that result in irregular heartbeats.
Abbott
AFib affects around 8 million Europeans over the age of 65, and this figure is anticipated to grow over the next 30 years.